Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
The headquarters of Valeant Pharmaceuticals International Inc., seen in Laval, Quebec November 9 2015. (CHRISTINNE MUSCHI/REUTERS)
The headquarters of Valeant Pharmaceuticals International Inc., seen in Laval, Quebec November 9 2015. (CHRISTINNE MUSCHI/REUTERS)

Valeant prices psoriasis treatment at $3,500 per month Add to ...

Canadian drugmaker Valeant Pharmaceuticals International Inc said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017.

Siliq is the lowest priced injectable biologic psoriasis treatment currently on the market, Valeant said on Friday.

The treatment, which blocks a cell receptor known as interleukin-17 to tamp down inflammation, will compete with a host of existing IL-17 inhibitors including Cosentyx from Novartis AG and Taltz from Eli Lilly & Co.

Looks like Valeant has sought to price this reasonably relative to Taltz and Cosentyx, Stifel analyst Annabel Samimy told Reuters.

Taltz's list price is $4,469 per month.

"But this is only list price – it's neither here nor there unless you know the rebates provided to payers. But optically, looks like Siliq is the better value based on the price and relative efficacy," Samimy said.

Siliq will also compete with other classes of drugs used to treat psoriasis such as Amgen Inc's Enbrel, Johnson & Johnson's Remicade and AbbVie Inc's Humira.

Valeant is trying to regain investor confidence following a tumultuous year in which its pricing strategy and ties to a specialty pharmacy led to a wider political and regulatory scrutiny.

The Canadian drugmaker's U.S.-listed shares were up about 1 percent at $8.98 in early trading on Friday.

Siliq secured U.S. approval in February, but the Food and Drug Administration slapped on its label a black box warning - the most severe given by the agency - calling attention to the risk of suicidal thoughts and behavior.

About 7.5 million in the United States suffer from psoriasis, according to the American Academy of Dermatology.

The disorder, characterized by raised, scaly skin patches, can be associated with other conditions, including diabetes and heart disease.

 

Editor's note: The list price for Taltz has been corrected in this story and a reference of pricing from an analyst has been removed.

 

 

Report Typo/Error

Also on The Globe and Mail

Money Monitor: How pet insurance helped one dog owner (The Canadian Press)

Next story

loading

Trending

loading

Most popular videos »

More from The Globe and Mail

Most popular